OnKure Therapeutics, Inc.

Listed Company

OKURCIK 0001637715NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-59.52M

Total Assets

$62.12M

Equity

$56.18M

Shares Out

13.67M

Op. Cash Flow

$-51.83M

Business

OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops precision small-molecule medicines targeting mutated drivers of cancer, with a focus on mutant-selective PI3Kα inhibitors. Its main product candidate is OKI-219, an orally administered, H1047R‑selective PI3Kα inhibitor in Phase 1, and it advances pan‑mutant and helical‑domain PI3Kα programs through discovery and preclinical development. Key business activities comprise discovery chemistry, preclinical studies, and clinical development programs across a PI3Kα-focused pipeline, supported by third‑party contract manufacturers. The company conducts international clinical trials and distributes investigational product via clinical trial sites in the United States, European Union, and Asia, while planning regulatory and commercialization efforts globally through potential partners and third‑party supply arrangements.

Summary from filing dated 2025-03-10

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	48	44	32	38	28
General and administrative	15	11	5	16	12
Total operating expenses	63	54	37	54	40
Loss from operations	−63	−54	−37	−54	−40
Interest income	3	2	2	—	—
Interest and other expense	−8,000	−300,000	—	—	—
Total other income (expense)	3	2	2	—	—
Net loss and comprehensive loss	−60	−53	−35	−52	−40
Net loss per share attributable to common stockholders: Basic	−4.4	−15.28	−124.41	−2.12	−2.19
Net loss per share attributable to common stockholders: diluted	−4.4	−15.28	−124.41	−2.12	−2.19
Weighted average shares outstanding: Basic	14	3	283,817	24	18
Weighted average shares outstanding: diluted	14	3	283,817	24	18

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	59	111	30	20	125
Prepaid expenses and other current assets	2	2	4	5	6
Total current assets	61	113	34	106	154
Property and equipment, net	618,000	1	1	453,000	212,000
Operating lease right-of-use asset	387,000	770,000	478,000	1	—
Other assets	273,000	109,000	58,000	84,000	78,000
Total assets	62	115	36	108	154
Accounts payable	1	3	3	2	2
Accrued expenses and other current liabilities	4	7	—	—	—
Operating lease liabilities, current portion	549,000	536,000	208,000	404,000	—
Total current liabilities	6	11	7	7	6
Long-term operating lease liabilities	—	549,000	466,000	1	—
Other long-term liabilities	12,000	—	—	—	167,000
Total liabilities	6	11	8	8	7
Commitments and contingencies	—	—	—	—	—
Additional paid-in capital	270	259	209,000	237	232
Accumulated deficit	−214	−155	−102	−137	−85
Total stockholders' equity	56	104	−102	−54	147
Total liabilities and stockholders' equity	62	115	36	108	154

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Share-based compensation expense	12	5	199,000	4	4
Depreciation and amortization	447,000	459,000	417,000	88,000	50,000
Amortization of right-of-use asset - operating	383,000	203,000	143,000	—	—
Loss on disposal of property and equipment	6,000	—	—	—	—
Amortization of debt issuance costs	—	142,000	—	—	—
Non-cash interest expense	—	120,000	—	—	—
Loss on sales of available-for-sale securities	—	54,000	—	17,000	—
Prepaid and other assets	289,000	2	−1	878,000	−5
Accounts payable, accrued and other liabilities	−5	−6	2	518,000	2
Lease liabilities	−536,000	−281,000	−210,000	−437,000	—
Other long-term liabilities	12,000	—	—	—	—
Net cash used in operating activities	−52	−51	−35	−47	−38
Proceeds from sales of marketable securities	—	16	—	—	—
Purchases of property and equipment	−46,000	−52,000	−246,000	−346,000	−198,000
Net cash (used in) provided by investing activities	−46,000	16	−246,000	−58	−23
Cash acquired in connection with the reverse recapitalization	—	58	—	—	—
Payment of reverse recapitalization transaction costs	−40,000	−2	—	—	—
Proceeds from issuance of convertible notes payable	—	6	—	—	—
Payment of issuance costs associated with the issuance of convertible notes payable	—	−142,000	—	—	—
Proceeds from sale of stock under the employee stock purchase plan	240,000	—	—	—	—
Proceeds from the issuance of common stock for exercises of stock options	—	26,000	—	—	556,000
Net cash provided by financing activities	163,000	116	53	471,000	132
Net decrease in cash and cash equivalents	−52	81	18	−105	71
Conversion of Series C Preferred Stock	—	130	—	—	—
Conversion of convertible note payable	—	6	—	—	—
Assets acquired in connection with the reverse recapitalization	—	17	—	—	—
Other liabilities assumed in connection with the reverse recapitalization	—	9	—	—	—
Reverse recapitalization transaction costs included in accounts payable	—	40,000	—	—	—
Concurrent Financing issuance costs included in accounts payable	—	37,000	—	—	—
Concurrent Financing issuance costs paid by Reneo prior to Merger	—	89,000	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro